Search

Displaying results 3801 - 3810 of 10000 in total
  1. Drug

    Ropidoxuridine

    go.drugbank.com/drugs/DB06485
    Investigational

    Ropidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.

    Categories: Heterocyclic Compounds, 1-RingSynonyms: 1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-5-IODOPYRIMIDIN-2(1H)-ONE, 2(1H)-PYRIMIDINONE, 1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-5-IODO-
  2. Drug

    Liatermin

    go.drugbank.com/drugs/DB06489
    Investigational

    Synonyms: r-metHuGDNF
  3. Drug

    Sufugolix

    go.drugbank.com/drugs/DB06494
    Experimental

  4. Drug

    L523S

    go.drugbank.com/drugs/DB06498
    Investigational

    [A175909] It has been investigated as a lung cancer vaccine. … According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S)

  5. Drug

    IGN101

    go.drugbank.com/drugs/DB06500
    Experimental

    IGN101 is an antibody-based cancer vaccine directed against epithelial cancers. It consists of 500 ug 17-1A antibody adsorbed on aluminum hydroxide.

  6. Drug

    AMGN-0007

    go.drugbank.com/drugs/DB06511
    Experimental

    Recombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.

  7. Drug

    Levovirin

    go.drugbank.com/drugs/DB06523
    Experimental

  8. Drug

    Ganstigmine

    go.drugbank.com/drugs/DB06525
    Experimental

    Ganstigmine is an orally active, geneserine derived, carbamate-based acetylcholinesterase inhibitor developed for the treatment of Alzheimer's disease.

  9. Drug

    Ragaglitazar

    go.drugbank.com/drugs/DB06533
    Experimental

    Categories: Heterocyclic Compounds, 1-Ring
  10. Drug

    Tesaglitazar

    go.drugbank.com/drugs/DB06536
    Investigational

    Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development. … Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance.